PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual mechanism of action in statin‐treated patients with very high apolipoprotein(a) concentration-Reference-Cited by-同舟云学术

PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual mechanism of action in statin‐treated patients with very high apolipoprotein(a) concentration

Published:2022-02-09 Issue:6 Volume:291 Page:870-876
ISSN:0954-6820
Container-title:Journal of Internal Medicine
language:en
Short-container-title:J Intern Med

Author:

Ying Qidi¹,Chan Dick C.¹^ORCID,Pang Jing¹,Marcovina Santica M.²,Barrett Peter Hugh R.³,Watts Gerald F.¹⁴

Affiliation:

1. Faculty of Health and Medical Sciences Medical School, University of Western Australia Perth Western Australia Australia

2. Medpace Reference Laboratories Cincinnati Ohio USA

3. Faculty of Medicine and Health University of New England Armidale New South Wales Australia

4. Department of Cardiology and Internal Medicine Lipid Disorders Clinic, Royal Perth Hospital Perth Western Australia Australia

Publisher

Wiley

Subject

Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/joim.13457

Reference20 articles.

1. Structure, function, and genetics of lipoprotein (a)

2. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association;Reyes‐Soffer G;Arterioscler Thromb Vasc Biol,2021

3. Emerging RNA Therapeutics to Lower Blood Levels of Lp(a)

4. HEART UK consensus statement on Lipoprotein(a): A call to action

5. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Mechanisms of PCSK9 Inhibitor Reducing Lipoprotein(a);PROG BIOCHEM BIOPHYS;2024

2. Identification of benzothiazoles as novel PCSK9 inhibitors;Bioorganic & Medicinal Chemistry Letters;2024-01

3. Surface LDLR is a major receptor for lipoprotein(a) clearance in male mice lacking PCSK9;Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids;2023-04

4. Relationship of apolipoprotein(a) isoform size with clearance and production of lipoprotein(a) in a diverse cohort;Journal of Lipid Research;2023-03

5. Application of PCSK9 Inhibitors in Lipid Metabolism and Arteriosclerosis;Advances in Clinical Medicine;2023